ClinTex

There is enough material to suggest that ClinTex is aiming to address a real need within the clinical trial field. Tokenomics for the project are straightforward with minimal bonuses applicable and a clear team vesting period. The acceptance of Binance coin in the ICO adds another level of interest and, although no partnership is stated or implied, investors may feel it increases the possibility of a future listing opportunity with the exchange.

Maybe most importantly, an able team is backed by experienced advisors and together they have shown the foresight to partner with useful allies within the blockchain arena and realm of medical services.

The downside column is much shorter but it should be noted that there is currently no working product and the roadmap suggests that some of the infrastructure will not be fully available until well into 2020 which could hamper uptake of the platform.

The whitepaper states that one of the reasons ClinTex ClinTex has partnered with Intellimed is that they will “…deploy the CTi platform in academic clinical research settings.”

This suggests that a firm footing for the initial launch of the platform has been established so it is the forward momentum of ClinTex, that includes expected on-boarding of other pharmaceutical companies in mid-2019, that contributors to the ICO will need to judge.

Given that they have first mover advantage in this particular specialised arena, the fundamentals appear to outweigh the minor concern and marks ClinTex as an ICO worthy of serious consideration.